Suven Pharmaceuticals Limited
Suven Pharmaceuticals Limited (SUVENPHAR.NS) Stock Competitors & Peer Comparison
See (SUVENPHAR.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SUVENPHAR.NS | ₹1,078.00 | -0.11% | 412.4B | 98.90 | ₹10.90 | N/A |
| SUNPHARMA.NS | ₹1,731.80 | +0.00% | 4.2T | 38.72 | ₹45.56 | +0.94% |
| SUNPHARMA.BO | ₹1,730.55 | +0.00% | 4.2T | 38.76 | ₹45.50 | +0.94% |
| DIVISLAB.BO | ₹6,254.85 | +0.00% | 1.7T | 68.71 | ₹93.12 | +0.47% |
| DIVISLAB.NS | ₹6,255.50 | +0.00% | 1.7T | 68.69 | ₹93.11 | +0.47% |
| TORNTPHARM.BO | ₹4,398.70 | -0.00% | 1.5T | 69.88 | ₹63.25 | +0.79% |
| TORNTPHARM.NS | ₹4,397.90 | +0.00% | 1.5T | 65.76 | ₹67.20 | +0.79% |
| DRREDDY.BO | ₹1,299.40 | +0.00% | 1.1T | 19.26 | ₹67.84 | +0.61% |
| DRREDDY.NS | ₹1,300.20 | +0.00% | 1.1T | 19.25 | ₹67.87 | +0.61% |
| LUPIN.NS | ₹2,250.20 | +0.00% | 1T | 22.60 | ₹101.43 | +0.52% |
Stock Comparison
SUVENPHAR.NS vs SUNPHARMA.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUNPHARMA.NS has a market cap of 4.2T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUNPHARMA.NS trades at ₹1,731.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUNPHARMA.NS's P/E ratio is 38.72. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUNPHARMA.NS's competition here
SUVENPHAR.NS vs SUNPHARMA.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUNPHARMA.BO has a market cap of 4.2T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUNPHARMA.BO trades at ₹1,730.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUNPHARMA.BO's P/E ratio is 38.76. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUNPHARMA.BO's competition here
SUVENPHAR.NS vs DIVISLAB.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, DIVISLAB.BO has a market cap of 1.7T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while DIVISLAB.BO trades at ₹6,254.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas DIVISLAB.BO's P/E ratio is 68.71. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check DIVISLAB.BO's competition here
SUVENPHAR.NS vs DIVISLAB.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, DIVISLAB.NS has a market cap of 1.7T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while DIVISLAB.NS trades at ₹6,255.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas DIVISLAB.NS's P/E ratio is 68.69. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check DIVISLAB.NS's competition here
SUVENPHAR.NS vs TORNTPHARM.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while TORNTPHARM.BO trades at ₹4,398.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas TORNTPHARM.BO's P/E ratio is 69.88. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check TORNTPHARM.BO's competition here
SUVENPHAR.NS vs TORNTPHARM.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while TORNTPHARM.NS trades at ₹4,397.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas TORNTPHARM.NS's P/E ratio is 65.76. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check TORNTPHARM.NS's competition here
SUVENPHAR.NS vs DRREDDY.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while DRREDDY.BO trades at ₹1,299.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas DRREDDY.BO's P/E ratio is 19.26. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check DRREDDY.BO's competition here
SUVENPHAR.NS vs DRREDDY.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while DRREDDY.NS trades at ₹1,300.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas DRREDDY.NS's P/E ratio is 19.25. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check DRREDDY.NS's competition here
SUVENPHAR.NS vs LUPIN.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while LUPIN.NS trades at ₹2,250.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas LUPIN.NS's P/E ratio is 22.60. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check LUPIN.NS's competition here
SUVENPHAR.NS vs LUPIN.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while LUPIN.BO trades at ₹2,251.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas LUPIN.BO's P/E ratio is 24.29. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check LUPIN.BO's competition here
SUVENPHAR.NS vs ZYDUSLIFE.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ZYDUSLIFE.NS has a market cap of 925.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ZYDUSLIFE.NS trades at ₹903.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ZYDUSLIFE.NS's P/E ratio is 18.76. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ZYDUSLIFE.NS's competition here
SUVENPHAR.NS vs ZYDUSLIFE.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ZYDUSLIFE.BO has a market cap of 925.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ZYDUSLIFE.BO trades at ₹904.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ZYDUSLIFE.BO's P/E ratio is 18.75. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ZYDUSLIFE.BO's competition here
SUVENPHAR.NS vs MANKIND.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, MANKIND.NS has a market cap of 889.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while MANKIND.NS trades at ₹2,054.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas MANKIND.NS's P/E ratio is 49.92. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check MANKIND.NS's competition here
SUVENPHAR.NS vs MANKIND.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, MANKIND.BO has a market cap of 889.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while MANKIND.BO trades at ₹2,053.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas MANKIND.BO's P/E ratio is 49.92. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check MANKIND.BO's competition here
SUVENPHAR.NS vs AUROPHARMA.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AUROPHARMA.BO has a market cap of 705.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AUROPHARMA.BO trades at ₹1,164.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AUROPHARMA.BO's P/E ratio is 20.61. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AUROPHARMA.BO's competition here
SUVENPHAR.NS vs AUROPHARMA.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AUROPHARMA.NS has a market cap of 703.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AUROPHARMA.NS trades at ₹1,164.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AUROPHARMA.NS's P/E ratio is 20.16. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AUROPHARMA.NS's competition here
SUVENPHAR.NS vs ALKEM.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ALKEM.NS has a market cap of 672.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ALKEM.NS trades at ₹5,495.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ALKEM.NS's P/E ratio is 28.35. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ALKEM.NS's competition here
SUVENPHAR.NS vs ALKEM.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ALKEM.BO has a market cap of 671.7B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ALKEM.BO trades at ₹5,496.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ALKEM.BO's P/E ratio is 28.31. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ALKEM.BO's competition here
SUVENPHAR.NS vs GLENMARK.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GLENMARK.NS has a market cap of 588.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GLENMARK.NS trades at ₹2,058.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GLENMARK.NS's P/E ratio is 55.35. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GLENMARK.NS's competition here
SUVENPHAR.NS vs GLENMARK.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GLENMARK.BO has a market cap of 588.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GLENMARK.BO trades at ₹2,061.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GLENMARK.BO's P/E ratio is 55.24. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GLENMARK.BO's competition here
SUVENPHAR.NS vs LAURUSLABS.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, LAURUSLABS.NS has a market cap of 581.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while LAURUSLABS.NS trades at ₹1,028.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas LAURUSLABS.NS's P/E ratio is 68.86. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check LAURUSLABS.NS's competition here
SUVENPHAR.NS vs LAURUSLABS.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, LAURUSLABS.BO has a market cap of 580.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while LAURUSLABS.BO trades at ₹1,029.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas LAURUSLABS.BO's P/E ratio is 68.75. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to LAURUSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check LAURUSLABS.BO's competition here
SUVENPHAR.NS vs SUVENPHAR.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SUVENPHAR.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUVENPHAR.BO's competition here
SUVENPHAR.NS vs IPCALAB.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, IPCALAB.NS has a market cap of 386.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while IPCALAB.NS trades at ₹1,515.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas IPCALAB.NS's P/E ratio is 42.57. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check IPCALAB.NS's competition here
SUVENPHAR.NS vs IPCALAB.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, IPCALAB.BO has a market cap of 386.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while IPCALAB.BO trades at ₹1,523.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas IPCALAB.BO's P/E ratio is 42.48. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check IPCALAB.BO's competition here
SUVENPHAR.NS vs AJANTPHARM.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AJANTPHARM.BO has a market cap of 377.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AJANTPHARM.BO trades at ₹2,950.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AJANTPHARM.BO's P/E ratio is 37.27. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AJANTPHARM.BO's competition here
SUVENPHAR.NS vs AJANTPHARM.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AJANTPHARM.NS has a market cap of 377.5B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AJANTPHARM.NS trades at ₹2,948.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AJANTPHARM.NS's P/E ratio is 37.24. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AJANTPHARM.NS's competition here
SUVENPHAR.NS vs JBCHEPHARM.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, JBCHEPHARM.BO has a market cap of 334.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while JBCHEPHARM.BO trades at ₹2,069.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas JBCHEPHARM.BO's P/E ratio is 44.03. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check JBCHEPHARM.BO's competition here
SUVENPHAR.NS vs JBCHEPHARM.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, JBCHEPHARM.NS has a market cap of 334.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while JBCHEPHARM.NS trades at ₹2,070.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas JBCHEPHARM.NS's P/E ratio is 44.00. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check JBCHEPHARM.NS's competition here
SUVENPHAR.NS vs EMCURE.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, EMCURE.NS has a market cap of 271.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while EMCURE.NS trades at ₹1,434.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas EMCURE.NS's P/E ratio is 31.19. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to EMCURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check EMCURE.NS's competition here
SUVENPHAR.NS vs PEL.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check PEL.NS's competition here
SUVENPHAR.NS vs WOCKPHARMA.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, WOCKPHARMA.NS has a market cap of 223.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while WOCKPHARMA.NS trades at ₹1,362.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas WOCKPHARMA.NS's P/E ratio is 1119.59. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check WOCKPHARMA.NS's competition here
SUVENPHAR.NS vs WOCKPHARMA.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, WOCKPHARMA.BO has a market cap of 223.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while WOCKPHARMA.BO trades at ₹1,361.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas WOCKPHARMA.BO's P/E ratio is 1117.36. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check WOCKPHARMA.BO's competition here
SUVENPHAR.NS vs ASTRAZEN.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ASTRAZEN.NS has a market cap of 221.7B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ASTRAZEN.NS trades at ₹8,800.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ASTRAZEN.NS's P/E ratio is 110.85. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ASTRAZEN.NS's competition here
SUVENPHAR.NS vs ASTRAZEN.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ASTRAZEN.BO has a market cap of 220.5B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ASTRAZEN.BO trades at ₹8,791.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ASTRAZEN.BO's P/E ratio is 110.08. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ASTRAZEN.BO's competition here
SUVENPHAR.NS vs PPLPHARMA.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, PPLPHARMA.BO has a market cap of 213B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while PPLPHARMA.BO trades at ₹159.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas PPLPHARMA.BO's P/E ratio is -129.80. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check PPLPHARMA.BO's competition here
SUVENPHAR.NS vs ERIS.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ERIS.BO has a market cap of 188B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ERIS.BO trades at ₹1,384.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ERIS.BO's P/E ratio is 43.83. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to ERIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ERIS.BO's competition here
SUVENPHAR.NS vs ERIS.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ERIS.NS has a market cap of 188B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ERIS.NS trades at ₹1,384.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ERIS.NS's P/E ratio is 43.72. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to ERIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ERIS.NS's competition here
SUVENPHAR.NS vs NATCOPHARM.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NATCOPHARM.BO has a market cap of 175.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NATCOPHARM.BO trades at ₹944.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NATCOPHARM.BO's P/E ratio is 11.39. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to NATCOPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NATCOPHARM.BO's competition here
SUVENPHAR.NS vs NATCOPHARM.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NATCOPHARM.NS has a market cap of 175.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NATCOPHARM.NS trades at ₹944.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NATCOPHARM.NS's P/E ratio is 11.25. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NATCOPHARM.NS's competition here
SUVENPHAR.NS vs NEULANDLAB.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NEULANDLAB.NS has a market cap of 171B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NEULANDLAB.NS trades at ₹13,366.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NEULANDLAB.NS's P/E ratio is 95.74. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NEULANDLAB.NS's competition here
SUVENPHAR.NS vs NEULANDLAB.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NEULANDLAB.BO has a market cap of 171B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NEULANDLAB.BO trades at ₹13,366.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NEULANDLAB.BO's P/E ratio is 95.71. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NEULANDLAB.BO's competition here
SUVENPHAR.NS vs GRANULES.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GRANULES.NS has a market cap of 145.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GRANULES.NS trades at ₹599.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GRANULES.NS's P/E ratio is 26.68. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GRANULES.NS's competition here
SUVENPHAR.NS vs GRANULES.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GRANULES.BO has a market cap of 145.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GRANULES.BO trades at ₹599.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GRANULES.BO's P/E ratio is 26.67. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GRANULES.BO's competition here
SUVENPHAR.NS vs APLLTD.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, APLLTD.NS has a market cap of 145.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while APLLTD.NS trades at ₹750.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas APLLTD.NS's P/E ratio is 23.06. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check APLLTD.NS's competition here
SUVENPHAR.NS vs APLLTD.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, APLLTD.BO has a market cap of 145.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while APLLTD.BO trades at ₹750.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas APLLTD.BO's P/E ratio is 23.02. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check APLLTD.BO's competition here
SUVENPHAR.NS vs JUBLPHARMA.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, JUBLPHARMA.NS has a market cap of 142.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while JUBLPHARMA.NS trades at ₹879.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas JUBLPHARMA.NS's P/E ratio is 32.93. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check JUBLPHARMA.NS's competition here
SUVENPHAR.NS vs JUBLPHARMA.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, JUBLPHARMA.BO has a market cap of 141.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while JUBLPHARMA.BO trades at ₹878.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas JUBLPHARMA.BO's P/E ratio is 32.80. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check JUBLPHARMA.BO's competition here
SUVENPHAR.NS vs GLS.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to GLS.NS's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GLS.NS's competition here
SUVENPHAR.NS vs GLS.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GLS.BO's competition here
SUVENPHAR.NS vs CAPLIPOINT.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, CAPLIPOINT.BO has a market cap of 131.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while CAPLIPOINT.BO trades at ₹1,711.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas CAPLIPOINT.BO's P/E ratio is 21.44. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to CAPLIPOINT.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check CAPLIPOINT.BO's competition here
SUVENPHAR.NS vs CAPLIPOINT.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, CAPLIPOINT.NS has a market cap of 131.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while CAPLIPOINT.NS trades at ₹1,712.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas CAPLIPOINT.NS's P/E ratio is 21.47. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check CAPLIPOINT.NS's competition here
SUVENPHAR.NS vs COHANCE.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, COHANCE.NS has a market cap of 118.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while COHANCE.NS trades at ₹309.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas COHANCE.NS's P/E ratio is 61.24. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to COHANCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check COHANCE.NS's competition here
SUVENPHAR.NS vs COHANCE.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, COHANCE.BO has a market cap of 118.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while COHANCE.BO trades at ₹309.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas COHANCE.BO's P/E ratio is 60.99. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to COHANCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check COHANCE.BO's competition here
SUVENPHAR.NS vs ALIVUS.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ALIVUS.NS has a market cap of 111.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ALIVUS.NS trades at ₹884.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ALIVUS.NS's P/E ratio is 20.50. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ALIVUS.NS's competition here
SUVENPHAR.NS vs ALIVUS.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ALIVUS.BO has a market cap of 111.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ALIVUS.BO trades at ₹884.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ALIVUS.BO's P/E ratio is 20.51. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ALIVUS.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ALIVUS.BO's competition here
SUVENPHAR.NS vs CAPPL.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check CAPPL.BO's competition here
SUVENPHAR.NS vs VIYASH.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, VIYASH.NS has a market cap of 95.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while VIYASH.NS trades at ₹219.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas VIYASH.NS's P/E ratio is 84.66. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check VIYASH.NS's competition here
SUVENPHAR.NS vs PGHL.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, PGHL.BO has a market cap of 86.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while PGHL.BO trades at ₹5,160.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas PGHL.BO's P/E ratio is 36.54. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check PGHL.BO's competition here
SUVENPHAR.NS vs PGHL.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, PGHL.NS has a market cap of 85.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while PGHL.NS trades at ₹5,161.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas PGHL.NS's P/E ratio is 36.03. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check PGHL.NS's competition here
SUVENPHAR.NS vs STAR.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, STAR.NS has a market cap of 79.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while STAR.NS trades at ₹861.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas STAR.NS's P/E ratio is 15.57. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check STAR.NS's competition here
SUVENPHAR.NS vs STAR.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, STAR.BO has a market cap of 79.5B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while STAR.BO trades at ₹860.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas STAR.BO's P/E ratio is 15.55. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check STAR.BO's competition here
SUVENPHAR.NS vs AKUMS.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AKUMS.NS has a market cap of 73.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AKUMS.NS trades at ₹483.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AKUMS.NS's P/E ratio is 22.88. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to AKUMS.NS's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AKUMS.NS's competition here
SUVENPHAR.NS vs AARTIPHARM.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AARTIPHARM.BO has a market cap of 64.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AARTIPHARM.BO trades at ₹692.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AARTIPHARM.BO's P/E ratio is 30.15. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AARTIPHARM.BO's competition here
SUVENPHAR.NS vs AARTIPHARM.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AARTIPHARM.NS has a market cap of 64.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AARTIPHARM.NS trades at ₹690.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AARTIPHARM.NS's P/E ratio is 30.06. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AARTIPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AARTIPHARM.NS's competition here
SUVENPHAR.NS vs SHILPAMED.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SHILPAMED.NS has a market cap of 64B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SHILPAMED.NS trades at ₹320.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SHILPAMED.NS's P/E ratio is 28.93. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SHILPAMED.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SHILPAMED.NS's competition here
SUVENPHAR.NS vs FDC.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, FDC.BO has a market cap of 59.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while FDC.BO trades at ₹370.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas FDC.BO's P/E ratio is 27.53. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check FDC.BO's competition here
SUVENPHAR.NS vs FDC.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, FDC.NS has a market cap of 59.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while FDC.NS trades at ₹368.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas FDC.NS's P/E ratio is 27.43. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check FDC.NS's competition here
SUVENPHAR.NS vs SEQUENT.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SEQUENT.NS's competition here
SUVENPHAR.NS vs SEQUENT.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SEQUENT.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SEQUENT.BO's competition here
SUVENPHAR.NS vs SPARC.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SPARC.NS has a market cap of 42.5B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SPARC.NS trades at ₹127.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SPARC.NS's P/E ratio is -15.87. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SPARC.NS's competition here
SUVENPHAR.NS vs SPARC.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SPARC.BO has a market cap of 42.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SPARC.BO trades at ₹127.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SPARC.BO's P/E ratio is -15.83. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SPARC.BO's competition here
SUVENPHAR.NS vs INNOVACAP.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, INNOVACAP.NS has a market cap of 38.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while INNOVACAP.NS trades at ₹671.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas INNOVACAP.NS's P/E ratio is 28.92. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check INNOVACAP.NS's competition here
SUVENPHAR.NS vs GUJTHEM.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GUJTHEM.NS has a market cap of 34.5B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GUJTHEM.NS trades at ₹319.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GUJTHEM.NS's P/E ratio is 71.89. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GUJTHEM.NS's competition here
SUVENPHAR.NS vs SUVEN.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUVEN.BO has a market cap of 34.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUVEN.BO trades at ₹149.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUVEN.BO's P/E ratio is -12.18. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SUVEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUVEN.BO's competition here
SUVENPHAR.NS vs SUVEN.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUVEN.NS has a market cap of 34.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUVEN.NS trades at ₹148.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUVEN.NS's P/E ratio is -12.16. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUVEN.NS's competition here
SUVENPHAR.NS vs AARTIDRUGS.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AARTIDRUGS.BO has a market cap of 33.7B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AARTIDRUGS.BO trades at ₹369.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AARTIDRUGS.BO's P/E ratio is 16.72. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AARTIDRUGS.BO's competition here
SUVENPHAR.NS vs AARTIDRUGS.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AARTIDRUGS.NS has a market cap of 33.7B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AARTIDRUGS.NS trades at ₹369.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AARTIDRUGS.NS's P/E ratio is 16.74. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AARTIDRUGS.NS's competition here
SUVENPHAR.NS vs SHILPAMED.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SHILPAMED.BO has a market cap of 32B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SHILPAMED.BO trades at ₹319.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SHILPAMED.BO's P/E ratio is 29.02. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SHILPAMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SHILPAMED.BO's competition here
SUVENPHAR.NS vs ORCHPHARMA.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ORCHPHARMA.NS has a market cap of 32B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ORCHPHARMA.NS trades at ₹647.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ORCHPHARMA.NS's P/E ratio is 169.06. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ORCHPHARMA.NS's competition here
SUVENPHAR.NS vs ORCHPHARMA.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ORCHPHARMA.BO has a market cap of 31.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ORCHPHARMA.BO trades at ₹645.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ORCHPHARMA.BO's P/E ratio is 167.47. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ORCHPHARMA.BO's competition here
SUVENPHAR.NS vs RPGLIFE.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, RPGLIFE.NS has a market cap of 31.7B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while RPGLIFE.NS trades at ₹1,882.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas RPGLIFE.NS's P/E ratio is 15.62. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check RPGLIFE.NS's competition here
SUVENPHAR.NS vs RPGLIFE.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, RPGLIFE.BO has a market cap of 31.5B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while RPGLIFE.BO trades at ₹1,886.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas RPGLIFE.BO's P/E ratio is 15.55. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check RPGLIFE.BO's competition here
SUVENPHAR.NS vs GUFICBIO.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GUFICBIO.BO has a market cap of 28B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GUFICBIO.BO trades at ₹281.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GUFICBIO.BO's P/E ratio is 49.22. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GUFICBIO.BO's competition here
SUVENPHAR.NS vs GUFICBIO.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GUFICBIO.NS has a market cap of 28B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GUFICBIO.NS trades at ₹281.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GUFICBIO.NS's P/E ratio is 49.17. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GUFICBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GUFICBIO.NS's competition here
SUVENPHAR.NS vs UNICHEMLAB.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, UNICHEMLAB.BO has a market cap of 25.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while UNICHEMLAB.BO trades at ₹355.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas UNICHEMLAB.BO's P/E ratio is 8.54. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check UNICHEMLAB.BO's competition here
SUVENPHAR.NS vs UNICHEMLAB.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, UNICHEMLAB.NS has a market cap of 25.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while UNICHEMLAB.NS trades at ₹354.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas UNICHEMLAB.NS's P/E ratio is 8.52. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check UNICHEMLAB.NS's competition here
SUVENPHAR.NS vs HIKAL.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, HIKAL.NS has a market cap of 24.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while HIKAL.NS trades at ₹200.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas HIKAL.NS's P/E ratio is -189.52. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to HIKAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check HIKAL.NS's competition here
SUVENPHAR.NS vs HIKAL.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, HIKAL.BO has a market cap of 24.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while HIKAL.BO trades at ₹200.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas HIKAL.BO's P/E ratio is 251.06. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to HIKAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check HIKAL.BO's competition here
SUVENPHAR.NS vs MOREPENLAB.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, MOREPENLAB.NS has a market cap of 24.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while MOREPENLAB.NS trades at ₹46.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas MOREPENLAB.NS's P/E ratio is 24.54. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check MOREPENLAB.NS's competition here
SUVENPHAR.NS vs MOREPENLAB.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, MOREPENLAB.BO has a market cap of 24.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while MOREPENLAB.BO trades at ₹46.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas MOREPENLAB.BO's P/E ratio is 24.66. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check MOREPENLAB.BO's competition here
SUVENPHAR.NS vs ALEMBICLTD.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ALEMBICLTD.NS has a market cap of 23.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ALEMBICLTD.NS trades at ₹92.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ALEMBICLTD.NS's P/E ratio is 7.30. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ALEMBICLTD.NS's competition here
SUVENPHAR.NS vs BLISSGVS.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, BLISSGVS.BO has a market cap of 23.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while BLISSGVS.BO trades at ₹210.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas BLISSGVS.BO's P/E ratio is 21.52. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check BLISSGVS.BO's competition here
SUVENPHAR.NS vs BLISSGVS.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, BLISSGVS.NS has a market cap of 23.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while BLISSGVS.NS trades at ₹210.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas BLISSGVS.NS's P/E ratio is 21.54. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check BLISSGVS.NS's competition here
SUVENPHAR.NS vs NOVARTIND.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NOVARTIND.BO has a market cap of 23.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NOVARTIND.BO trades at ₹945.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NOVARTIND.BO's P/E ratio is 23.76. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NOVARTIND.BO's competition here
SUVENPHAR.NS vs SOLARA.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SOLARA.NS has a market cap of 22.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SOLARA.NS trades at ₹473.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SOLARA.NS's P/E ratio is -98.27. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SOLARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SOLARA.NS's competition here
SUVENPHAR.NS vs SOLARA.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SOLARA.BO has a market cap of 22.7B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SOLARA.BO trades at ₹472.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SOLARA.BO's P/E ratio is -97.91. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SOLARA.BO's competition here
SUVENPHAR.NS vs IOLCP.NS Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, IOLCP.NS has a market cap of 21.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while IOLCP.NS trades at ₹71.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas IOLCP.NS's P/E ratio is 18.93. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check IOLCP.NS's competition here
SUVENPHAR.NS vs IOLCP.BO Comparison February 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, IOLCP.BO has a market cap of 21.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while IOLCP.BO trades at ₹71.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas IOLCP.BO's P/E ratio is 18.92. In terms of profitability, SUVENPHAR.NS's ROE is +0.13%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check IOLCP.BO's competition here